While the correction of genetic defect is essential, combination with other adjuvant therapies which do not rely solely on myostatin inhibition, but also other TGF-beta family members regulating muscle differentiations might be more beneficial for DMD therapies. This evidence concerns the gene MSTN and Duchenne muscular dystrophy.